antidepressants

shutterstock_129836540

Introduction

Antidepressants are medications used in the treatment of depression, but many can also be used in conditions such as anxiety disorders and obsessive compulsive disorder. Most antidepressants are taken orally.

What we already know

Antidepressants can be divided into six groups, based on their mechanism of action:

  1. Selective Serotonin Reuptake Inhibitors (SSRIs)“ e.g. Citalopram, Sertraline
  2. Serotonin-Noradrenaline Reuptake Inhibitors (SNRIs)“ e.g. Venlafaxine, Duloxetine
  3. Noradrenergic and Specific Serotonergic Antidepressants (NaSSAs) e.g. Mirtazapine
  4. Tricyclic Antidepressants (TCAs)“ e.g. Amitriptyline, Imipramine
  5. Monoamine Oxidase Inhibitors (MAO-Is) e.g. Phenelzine, Moclobemide
  6. Miscellaneous“ e.g. Bupropion, Trazodone, Reboxetine

Side effects depend on the mechanism of action and can vary from person to person.

NICE guidelines suggest use of antidepressants in moderate or severe cases of depression only. The risks of antidepressant medication use in mild depression outweigh the benefits, so other forms of therapy (e.g. CBT) are recommended in these cases.

Areas of uncertainty

  • The exact mechanisms of action – we are yet to find out exactly why and how many of the antidepressants work (there are inconsistencies in the monoamine theory of depression)
  • How to limit side effects associated with antidepressant use
  • How many people experience withdrawal effects and how best to withdraw from antidepressants
  • Using antidepressants in special groups – limited data exists for which antidepressants (if any) are best to use in pregnant women, children and the elderly

What’s in the pipeline

  • Ketamine has been shown to have promising antidepressant effects, although further randomised placebo-controlled trials are needed (Coyle and Laws, 2015)
  • Research is ongoing into the biological causes of depression and it is hoped that when this is better understood, therapy can be targeted towards the exact cause
  • Further research is also being conducted into the long term effects of antidepressants
  • Research aimed at developing more personalised treatment for depression is also underway

References

NICE guidelines CG90 (2009) ‘Depression in adults: The treatment and management of depression in adults’ [PDF]

Semple, D. and Smyth, R. (eds.) (2013) Oxford Handbook of Psychiatry. 3rd ed. Oxford: Oxford University Press. (Publisher)

Coyle, C. M. and Laws, K. R. (2015), ‘The use of ketamine as an antidepressant: a systematic review and meta-analysis.’ Hum. Psychopharmacol Clin Exp, doi: 10.1002/hup.2475 [Abstract]

Acknowledgement

Written by: Josephine Neale
Reviewed by: Helge Hasselmann
Last updated: Jun 2019
Review due: Jun 2020

Our antidepressants Blogs

New RCT shows that adding CBT to usual care helps people with treatment resistant depression

shutterstock_117069988

The CoBalT trial was published last week in the Lancet. This important randomised controlled trial (RCT) examined the effectiveness of cognitive behavioural therapy (CBT) as an add-on treatment to usual care for people with treatment resistant depression. Previous studies have shown that only around one third of people with depression respond well to treatment with [read the full story…]

Uncertainty over what works best to prevent relapse of childhood depression

shutterstock_74330686

Much of the research about depression in children and adolescents focuses on how to treat the illness during the acute phase. This review from the Cochrane Depression, Anxiety and Neurosis Review Group is more concerned with the ways in which interventions can be used to prevent relapse or recurrence of depressive disorders. The review looks specifically at two [read the full story…]

Antidepressants and suicide risk: retrospective cohort study reports cautious findings

shutterstock_111380762

Research has shown that antidepressant use can lead to a non-significant increase in the risk of suicidal thoughts and behaviour in people aged under 25 (Stone et al, BMJ 2009). This subject rightly received a large amount of media coverage a few years ago and it remains an area where new studies can add to [read the full story…]

Weak evidence comparing duloxetine to other antidepressants, says new Cochrane review

Antipsychotics can help with the neuropsychiatric symptoms of dementia, but they are also associated with a range of serious adverse events.

There are many different antidepressants to choose from when treating acute depression, so it’s always helpful to see a systematic review that looks at the efficacy, acceptability and tolerability of the different drugs. This new Cochrane review compares duloxetine hydrochloride (one of the newer drugs) with other antidepressants and finds little high quality evidence upon [read the full story…]

Little good evidence currently available to support the effectiveness of antidepressants in the treatment of orofacial pain

shutterstock_7431811

Orofacial pain is a relatively common and is categorized into musculoskeletal; neuropathic; vascular; neurovascular; idiopathic; pain caused by local, distant, or systemic pathology; and psychogenic.  Diagnosis can be challenging when psychosocial factors are present and while antidepressants have been used as a treatment there remains some controversy.  The aim of this review was to assess [read the full story…]

Genetic tests unlikely to help improve drug treatment for depression, according to new cohort study

shutterstock_58224664

There has been a lot of discussion over recent years about the ways in which genetic testing may help make the treatment of depression become more targeted and effective. The theory is that genetic markers may help predict how different people are likely to respond to different drugs. This is clearly something that would interest [read the full story…]

Scotland sees increase in prescribing rates for mental health drugs

shutterstock_57066451

The Scottish Government have published their annual summary of prescribing statistics for mental health drugs. The report shows increases in the prescribing rates for all groups of drugs over the last 12 months. The prescribing costs of some groups of drugs have also risen (ADHD, dementia, depression) although other groups have seen a decline (insomnia [read the full story…]

Escitalopram provides cost-effective remission from depression, according to new meta-analysis

shutterstock_2455480

I really enjoyed the discussion in the Guardian over the weekend about poor quality trials and pharmaceutical industry techniques that overhype their drugs in an attempt to shift units. Ben Goldacre’s new Bad Pharma book is well worth a read. New reviews about antidepressants come thick and fast and it’s often hard to know what [read the full story…]

How should we personalise treatment for adults with depression?

shutterstock_65982793

One of the criticisms that health professionals sometimes make of evidence-based research is that individual studies or reviews do not apply to the specific patient they are caring for. Of course, each patient is unique with their own values and preferences, as well as their own particular clinical characteristics, genetic make-up, biological markers and sociodemographic [read the full story…]

The risks of benzodiazepines, antidepressants and antipsychotics in adults with schizophrenia

shutterstock_71903914

Polypharmacy is the simultaneous use of two or more drugs to treat a single health condition. Polypharmacy is often used in the treatment of schizophrenia where people are regularly prescribed two or more antipsychotics, as well as antidepressants and/or benzodiazepines, although there is little evidence to prove that these combinations are more effective than monotherapy. [read the full story…]